Regulatory Momentum Baebies has FDA Breakthrough Device Designation for its Anti-Factor Xa test on the FINDER platform and has earned ADLM disruptive technology awards. This regulatory validation can be leveraged to accelerate conversations with hospitals, labs, and point-of-care networks seeking faster access to anticoagulation monitoring and multi-panel diagnostics.

Distributed Testing Advantage The FINDER platform is built for multiplex, low-volume testing in central labs and at the point of care, with a next-generation handheld platform in development. This creates sales opportunities in ambulatory clinics, urgent care centers, and regional hospitals seeking portable, rapid diagnostics across molecular, coagulation, and chemistry panels.

Pediatric Global Reach A strong emphasis on early disease detection for children and adults is evident from the SEEKER newborn screening use case in Italy and the current pediatric-focused panels. The opportunity lies in expanding newborn screening programs, pediatrics departments, and adult health monitoring in new geographies including expansion through existing distributors.

Channel Growth Existing partnerships with Technopath and Medical Horizons demonstrate a scalable distribution model. There is potential to broaden channel reach in Europe, Asia-Pacific, and the Americas by onboarding additional distributors and hospital systems to deploy FINDER panels widely.

Growth Finance With revenue in the tens of millions and a track record of federal funding support from NIH/NIAID, Baebies can leverage government-funded pilots and co-development opportunities to validate and deploy tests in targeted markets such as infectious disease panels and anticoagulation monitoring, accelerating customer adoption.